RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ultragenyx Pharmaceutical Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $112.00M | $89.00M | $101.68M | $94.99M | $81.00M | $91.00M | $71.46M | $77.25M | $73.81M | $62.49M | $51.24M | $42.35M | 52.3% | +38.3% |
| Royalty revenue | $102.00M | $47.00M | $105.60M | $64.94M | $86.00M | $48.00M | $93.19M | $62.24M | $73.22M | $46.34M | $76.08M | $55.70M | 47.7% | +18.6% |
| Collaboration and license | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $0 | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $121.00M | $59.00M | $132.75M | $83.54M | $103.00M | $58.00M | $116.52M | $76.91M | $88.89M | $57.68M | $92.77M | $67.81M | 56.5% | +17.5% |
| Latin America | $51.00M | $42.00M | $38.78M | $43.36M | $33.00M | $55.00M | $18.85M | $38.05M | $38.93M | $35.18M | $17.90M | $17.23M | 23.8% | +54.5% |
| Europe, Middle East, and Africa | $35.00M | $31.00M | $30.39M | $27.88M | $27.00M | $23.00M | $25.65M | $22.22M | $16.16M | $15.97M | $15.65M | $13.01M | 16.4% | +29.6% |
| Asia-Pacific | $7.00M | $4.00M | $5.36M | $5.15M | $4.00M | $3.00M | $3.64M | $2.31M | $3.05M | $0 | $822.00K | $0 | 3.3% | +75.0% |
| Europe | – | – | – | – | – | – | – | – | – | $15.97M | $15.18M | $13.01M | – | – |
| Japan | – | – | – | – | – | – | – | – | – | $0 | $1.05M | $0 | – | – |
From the segment and revenue-disaggregation notes of Ultragenyx Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.